Nazar Al Jassar

Director at Aegis Ventures | Previously OxfordVR and McKinsey

📍 United States🔄 Updated October 2026💼 6 investments📅 3 years investing🗓 Last invested Mar 2026
VC🌍 United StatesInvested this year
6
Total investments
4
Early stage
0
Mid stage
0
Late stage
3y
Years active

Portfolio

6 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
Mar 2026
Our goal is to eliminate preventable brain injury at birth, reduce the rate of unnecessary caesarean sections, and improve outcomes for both the mother and baby. Fetal heart rate monitoring is used in 90% of labors to assess the babys neurological health and has been associated with a 5x increase in C-section rates. Despite decades of use, it has not decreased fetal brain injury and has been associated with an adverse trend in overall C-section rates, resulting in extremely high maternal morbidity and mortality. Electroencephalogram (EEG), measuring brain waves via electrodes, is a more accurate and earlier indicator of the babys neurological health. However the previously proven method is invasive, requiring a scalp electrode on the baby during labor, and is not feasible at scale or in varying fetal positions. We have developed a new, non-invasive method & technology that harnesses the clinical promise of EEG without compromising the health of the mother or baby. Better monitoring will lead to better outcomes both for mother and child, in terms of avoiding brain injury during delivery and avoiding unnecessary C-sections and better matching C-sections or other interventions to clinically appropriate situations.
Investor
Feb 2025
Access high-quality, anonymized imaging and multi-modal data, backed by expert guidance and unwavering security — because your innovations deserve nothing less.
Investor
Jul 2024
Optain is a medical device and software company based in New York City and with roots in Australia. We are innovating to set the new benchmark in accurate and efficient patient care. We empower people with advanced AI and automation, using the eye as the gateway to detect and prevent diseases in their earliest stages.
Investor
Mar 2024
Ascertain is a revolutionary new partnership between Northwell Health and Aegis Ventures. We are a team of clinicians, engineers, and business leaders with the shared goal of developing impactful AI solutions which enable healthcare providers to better serve their communities and support those delivering care. Ascertain combines leading medical, technology, and business resources with Northwell Health’s deep insights and large datasets to launch healthcare AI companies at scale—addressing healthcare’s most challenging quality, access, and equity problems.
Angel Investor
Nov 2023
Rabbit is a micro-mobility platform offering rides and day rentals via electric vehicles such as scooters, bikes and other light vehicles.
Board Observer
Feb 2023
Caire is a comprehensive patient engagement platform designed to enhance patient experiences and streamline clinician workflows using intelligent AI agents. We are a team of clinicians, engineers, designers, and product managers with a shared goal of developing impactful AI solutions to create a healthier, more equitable, and sustainable healthcare ecosystem.
Experience · 7 entries
All (7)
Investments (6)
Board (1)
2026
Investor
Mar 2026
Our goal is to eliminate preventable brain injury at birth, reduce the rate of unnecessary caesarean sections, and improve outcomes for both the mother and baby. Fetal heart rate monitoring is used in 90% of labors to assess the babys neurological health and has been associated with a 5x increase in C-section rates. Despite decades of use, it has not decreased fetal brain injury and has been associated with an adverse trend in overall C-section rates, resulting in extremely high maternal morbidity and mortality. Electroencephalogram (EEG), measuring brain waves via electrodes, is a more accurate and earlier indicator of the babys neurological health. However the previously proven method is invasive, requiring a scalp electrode on the baby during labor, and is not feasible at scale or in varying fetal positions. We have developed a new, non-invasive method & technology that harnesses the clinical promise of EEG without compromising the health of the mother or baby. Better monitoring will lead to better outcomes both for mother and child, in terms of avoiding brain injury during delivery and avoiding unnecessary C-sections and better matching C-sections or other interventions to clinically appropriate situations.
2025
Investor
Feb 2025
Access high-quality, anonymized imaging and multi-modal data, backed by expert guidance and unwavering security — because your innovations deserve nothing less.
2024
Investor
Jul 2024
Optain is a medical device and software company based in New York City and with roots in Australia. We are innovating to set the new benchmark in accurate and efficient patient care. We empower people with advanced AI and automation, using the eye as the gateway to detect and prevent diseases in their earliest stages.
Investor
Mar 2024
Ascertain is a revolutionary new partnership between Northwell Health and Aegis Ventures. We are a team of clinicians, engineers, and business leaders with the shared goal of developing impactful AI solutions which enable healthcare providers to better serve their communities and support those delivering care. Ascertain combines leading medical, technology, and business resources with Northwell Health’s deep insights and large datasets to launch healthcare AI companies at scale—addressing healthcare’s most challenging quality, access, and equity problems.
2023
Angel Investor
Nov 2023
Rabbit is a micro-mobility platform offering rides and day rentals via electric vehicles such as scooters, bikes and other light vehicles.
Show all 7 entries ↓
Investment activity
2023–2026 · 6 investments
20232202422025120261
Recent (last 2 years)Earlier